Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel PCR Test Could Quickly Distinguish Breast Cancer from Benign Tumors

By LabMedica International staff writers
Posted on 06 Sep 2021
A novel laboratory test in development may be used to help quickly distinguish breast cancer from benign disease.

The breast cancer detection assay (BCDA) developed by researchers at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) examines cells from enlarged lymph nodes in the armpit adjacent to a breast and finds chemical markers that indicate metastatic breast cancer or a benign condition, such as an infection. More...
If validated in larger studies, this test could be used in outpatient settings to help providers more quickly determine the extent of disease and more effectively design treatment plans.

BCDA measures DNA methylation - a chemical alteration in DNA that can be an indicator of cancer - in 10 tumor-specific genes from fluid aspirates of the breast lesion and, in this study, the enlarged lymph node. It returns results within five hours and consists of a GeneXpert system that runs cartridges tailored for polymerase chain reaction (PCR) diagnostics. The automated cartridge-based test being studied detects trace amounts of genetic material, and is accompanied by a computer pre-loaded with software to analyze the data. It has three cartridges that hold chemicals to detect methylated DNA from fluid obtained from the patient’s breast growth or lymph nodes.

The researchers first applied the test to fine needle aspirate samples from a clinical study conducted in China of 218 patients (108 found to have cancer and 110 found to be benign) having sentinel lymph node biopsy. The sentinel node is the first lymph node to which breast cancer is likely to spread. The surgeon injects a dye into the breast lesion to find the sentinel lymph node, which is the first to turn blue. During sentinel node biopsy, this lymph node is removed and studied for the presence of cancer cells. The BCDA test identified cancer with nearly 91% accuracy and benign disease with 99% accuracy, and it was better than cytology - the search under a microscope for breast cancer cells in sections of the lymph node.

Researchers also validated the test in a second collection of 125 aspiration samples from 72 patients (47 from China and 25 from the U.S.) with enlarged malignant lymph nodes and 53 patients (28 from China and 25 from the U.S.) with benign breast disease. Samples were retrieved in an outpatient setting before patients started chemotherapy. In this group, the BCDA test identified those with cancer with 94% accuracy, and those without cancer with 92.5% accuracy.

Understanding lymph node status is an important factor in developing breast cancer treatment regimens because it can indicate possible metastasis, or cancer spread, according to the researchers. Various imaging tests including ultrasound, mammography and MRI can provide some information on axillary lymph nodes prior to surgery to aid in staging and treatment. However, the accuracy of these techniques can be relatively low. Cytology and histopathology, a more in-depth study of cells and tissue under a microscope, depend on the expertise and availability of a pathologist, which are often not common in middle and low income countries.

“A simple test with a high level of sensitivity and specificity as well as a quick turnaround time for accurate determination of a suspicious lymph node as benign or positive for cancer is urgently needed,” said senior study author Saraswati Sukumar, Ph.D., Barbara B. Rubenstein Professor of Oncology and professor of pathology at the Johns Hopkins University School of Medicine. “BCDA can provide results within a few hours of the fine needle aspiration procedure, reducing time to diagnosis.” She adds that test results also could be used to determine which patients with breast cancers need to have more invasive lymph node dissection measures.

“This test could be a really great adjunct to the detection of breast cancer,” added Sukumar. “The assay is self-contained and the answers are derived from a computer, so any technician, with a little training, can do it.”

Related Links:
Johns Hopkins Kimmel Cancer Center


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.